| In millions, except per share items | Jun-30-21 | Mar-31-21 | Sep-30-20 | Jun-30-20 | Jun-05-20 | Mar-31-20 | Mar-05-20 | Dec-31-19 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 8-K | 10-Q | 8-K | 10-K |
| Revenues: |
| Company product sales | | | 89.5 | 93.8 | | 75.0 | | 64.3 |
| Topical | | | 37.0 | 38.3 | | 42.5 | | 46.2 |
| Injectables | | | 12.7 | 15.8 | | 16.4 | | 18.1 |
| Total revenues [+] | | | 51.3 | 55.5 | | 60.2 | | 65.9 |
| Net interest income | | | -13.9 | | | | | -21.2 |
| Revenue growth [+] | | | -23.0% | -16.6% | | -6.6% | | 0.0% |
| Company product sales | | | 40.1% | 51.2% | | 27.4% | | 7.9% |
| Topical | | | -15.9% | -7.2% | | 17.3% | | 31.4% |
| Injectables | | | -35.7% | -24.1% | | -27.3% | | -25.9% |
| Contract manufacturing sales | | | -57.2% | -77.8% | | -80.8% | | -77.5% |
| Cost of goods sold | | | 47.9 | 44.9 | | 43.6 | | 42.4 |
| Gross profit | | | 3.4 | 10.6 | | 16.6 | | 23.5 |
| Gross margin | | | 6.6% | 19.0% | | 27.6% | | 35.7% |
| Selling, general and administrative [+] | | | 23.3 | 21.8 | | 22.0 | | 20.8 |
| Sales and marketing | | | 18.2 | 16.7 | | 16.9 | | |
| General and administrative | | | | | | | | 5.1 |
| Research and development | | | 9.1 | 8.8 | | 9.6 | | 10.8 |
| EBITDA [+] | | | -22.3 | -13.3 | | -8.2 | | -1.3 |
| EBITDA growth | | | 3281.8% | 446.5% | | -2.2% | | -86.0% |
| EBITDA margin | | | -43.5% | -23.9% | | -13.6% | | -2.0% |
| Depreciation | | | 3.9 | 3.9 | | 3.8 | | 3.7 |
| EBITA | | | -26.2 | -17.2 | | -12.0 | | -5.0 |
| EBITA margin | | | -51.1% | -30.9% | | -19.9% | | -7.6% |
| Amortization of intangibles | | | 2.8 | 2.9 | | 3.0 | | 3.0 |
| EBIT [+] | | | -29.0 | -20.0 | | -15.0 | | -8.0 |
| EBIT growth | | | 298.1% | 129.7% | | 4.6% | | -46.9% |
| EBIT margin | | | -56.5% | -36.1% | | -24.8% | | -12.2% |
| Non-recurring items [+] | | | | | | 8.4 | | |
| Asset impairment | | | | | | 8.4 | | |
| Interest expense | | | | 13.4 | | 5.9 | | |
| Interest expense | | | | 13.4 | | 5.9 | | |
| Other income (expense), net [+] | | | 3.9 | -11.8 | | -13.9 | | -17.0 |
| Gain (loss) on debt retirement | | | 10.0 | | | | | -0.9 |
| Unrealized gain/loss on derivatives | | | -1.5 | -5.8 | | -1.3 | | |
| Gain (loss) on foreign currency transactions | | | 3.3 | -0.7 | | -2.3 | | -1.5 |
| Pre-tax income | | | -46.9 | -53.5 | | -43.1 | | -25.0 |
| Income taxes | | | 0.1 | 0.0 | | 0.1 | | 0.1 |
| Tax rate | | | | -0.1% | | | | |
| Net income | | | -47.0 | -53.6 | | -43.2 | | -25.1 |
| Net margin | | | -91.5% | -96.6% | | -71.8% | | -38.1% |
| |
| Basic EPS [+] | | | ($2.65) | ($3.05) | | ($2.47) | | ($0.85) |
| Growth | | | 128.8% | 309.0% | | 229.8% | | 25.3% |
| Diluted EPS [+] | | | ($2.65) | ($3.05) | | ($2.47) | | ($0.85) |
| Growth | | | 128.8% | 309.0% | | 229.8% | | 25.3% |
| |
| Shares outstanding (basic) [+] | | | 17.7 | 17.6 | | 17.5 | | 29.6 |
| Growth | | | -40.0% | -57.8% | | -67.4% | | -44.7% |
| Shares outstanding (diluted) [+] | | | 17.7 | 17.6 | | 17.5 | | 29.6 |
| Growth | | | -40.0% | -57.8% | | -67.4% | | -44.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |